Tasly Pharmaceutical Group Co., Ltd. (600535.SH) Latest Company News

Oct 23, 2026, 08:33 UTC
Tasly reported third-quarter 2026 revenue of CNY 1.873 billion, down 7.41% year over year, attributable net profit of CNY 210 million, up 0.10%, and adjusted net profit of CNY 249 million, up 31.45%.
Source:
- finance.sina.cn
Oct 23, 2026, 08:33 UTC
Tasly reported 2026 first-three-quarter revenue of CNY 6.074 billion, down 3.76% year over year, attributable net profit of CNY 1.103 billion, up 12.01%, and adjusted net profit of CNY 1.119 billion, up 34.96%.
Source:
- finance.sina.cn
Oct 23, 2026, 08:33 UTC
Tianjin Tasly Pharmaceutical terminated clinical development of the TSL-1502 capsule and will fully impair its capitalized development costs of RMB 84.4179 million.
Source:
- finance.sina.cn
Oct 15, 2026, 09:47 UTC
China’s National Medical Products Administration approved a drug registration certificate for Jiangsu Tasly Diyi Pharmaceutical’s 2 mg raltitrexed for injection, deemed to have passed generic drug consistency evaluation.
Source:
- finance.sina.cn
Oct 14, 2026, 07:51 UTC
China's National Medical Products Administration approved TDX105 granules for Phase II and III clinical trials for certain chemotherapy- or targeted-therapy-related skin reactions.
Source:
- finance.sina.cn
Oct 9, 2026, 08:40 UTC
China’s National Medical Products Administration approved a drug registration certificate for injectable indocyanine green made by Tasly’s wholly owned subsidiary Tianjin Tasly Pride Pharmaceutical Co., Ltd.
Source:
- finance.sina.cn
Aug 31, 2026, 21:41 UTC
Tasly's net profit attributable to shareholders increased by 15.23% in the first half of 2026 despite a slight revenue decline, with 10 products newly included in the 2026 National Essential Medicines List.
Source:
- wap.eastmoney.com
Aug 21, 2026, 15:58 UTC
Tasly Pharmaceutical Group announced that 10 of its products, including two exclusive products Jinghua Weikang Jiaowan and Shaoma Zhijing Granules, were newly included in the 2026 National Essential Medicines List.
Source:
- wap.eastmoney.com
Aug 21, 2026, 10:33 UTC
Tasly Pharmaceutical Group announced a cash dividend of 2.4 yuan per 10 shares (tax inclusive), totaling 359 million yuan (tax inclusive).
Source:
- finance.sina.cn
Aug 21, 2026, 10:30 UTC
Tasly Pharmaceutical Group reported first-half revenue of 4.20 billion RMB and net profit of 892.7 million RMB.
Source:
- finance.sina.cn
- wap.eastmoney.com
Aug 10, 2026, 09:26 UTC
Tasly announced executive changes: Xi Kai to become general manager and be added as non-independent director, Cai Jinyong to become chairman, and Zhong Jiang to step down as non-independent director.
Source:
- finance.sina.cn
Jul 17, 2026, 09:34 UTC
Tianjin Tasly Pharmaceutical's subsidiary Tasly Biologics received regulatory approval from the National Medical Products Administration to conduct clinical trials for its drug Puyouke (recombinant human prourokinase for injection) in an expanded time window for acute ischemic stroke patients.
Source:
- finance.sina.cn
Jul 14, 2026, 09:29 UTC
Tianjin Tasly Pharmaceutical Co., Ltd. announced its 2026 semi-annual financial results, reporting net profit of 893 million yuan, up 15.23% year-on-year.
Source:
- finance.sina.cn
- rttnews.com

600535.SH

Tasly reported third-quarter 2026 revenue of CNY 1.873 billion, down 7.41% year over year, attributable net profit of CNY 210 million, up 0.10%, and adjusted net profit of CNY 249 million, up 31.45%.

Tasly reported 2026 first-three-quarter revenue of CNY 6.074 billion, down 3.76% year over year, attributable net profit of CNY 1.103 billion, up 12.01%, and adjusted net profit of CNY 1.119 billion, up 34.96%.

Tianjin Tasly Pharmaceutical terminated clinical development of the TSL-1502 capsule and will fully impair its capitalized development costs of RMB 84.4179 million.

China’s National Medical Products Administration approved a drug registration certificate for Jiangsu Tasly Diyi Pharmaceutical’s 2 mg raltitrexed for injection, deemed to have passed generic drug consistency evaluation.

China's National Medical Products Administration approved TDX105 granules for Phase II and III clinical trials for certain chemotherapy- or targeted-therapy-related skin reactions.

China’s National Medical Products Administration approved a drug registration certificate for injectable indocyanine green made by Tasly’s wholly owned subsidiary Tianjin Tasly Pride Pharmaceutical Co., Ltd.

Tasly's net profit attributable to shareholders increased by 15.23% in the first half of 2026 despite a slight revenue decline, with 10 products newly included in the 2026 National Essential Medicines List.

Tasly Pharmaceutical Group announced that 10 of its products, including two exclusive products Jinghua Weikang Jiaowan and Shaoma Zhijing Granules, were newly included in the 2026 National Essential Medicines List.

Tasly Pharmaceutical Group announced a cash dividend of 2.4 yuan per 10 shares (tax inclusive), totaling 359 million yuan (tax inclusive).

Tasly Pharmaceutical Group reported first-half revenue of 4.20 billion RMB and net profit of 892.7 million RMB.

Tasly announced executive changes: Xi Kai to become general manager and be added as non-independent director, Cai Jinyong to become chairman, and Zhong Jiang to step down as non-independent director.

Tianjin Tasly Pharmaceutical's subsidiary Tasly Biologics received regulatory approval from the National Medical Products Administration to conduct clinical trials for its drug Puyouke (recombinant human prourokinase for injection) in an expanded time window for acute ischemic stroke patients.

Tianjin Tasly Pharmaceutical Co., Ltd. announced its 2026 semi-annual financial results, reporting net profit of 893 million yuan, up 15.23% year-on-year.